Dr. Somer on the Expansion of Biosimilars in Oncology

November 22, 2019
Bradley G. Somer, MD
Bradley G. Somer, MD

Partner | Cancer Centers | <b> West Cancer Center</b>

Bradley G. Somer, MD, discusses the importance of taking a proactive approach towards the use of biosimilars in oncology.

Bradley G. Somer, MD, associate professor, Department of Hematology and Medical Oncology, University of Tennessee Health Science Center, medical oncologist, senior partner, Executive Cancer Council, and head of strategic expansion/development, West Cancer Center Research Program, West Cancer Center, discusses the importance of taking a proactive approach towards the use of biosimilars in oncology.

A number of biosimilars are poised to enter the marketplace, explains Somer. As such, Somer advises that practices form a small committee to aimed at optimizing biosimilars once they become available.

This group could include oncology pharmacists, quality committee individuals, as well as other investigators within the practice, concludes Somer.


x